RAlphs......I'm sure they will when it gets published...Anp were asked to submit.the outstanding data..Atl1103 for Acromegaly is a winner..Licence fees will be greater.because we have orphan drug designation in the US and Europe...
Scientific Publication
A manuscript entitled “Antisense Oligonucleotide Therapy in Acromegaly: A Randomized Phase II Study” has recently been submitted for publication in a high-quality peer reviewed scientific journal. The lead author of the publication is Dr Peter Trainer, Professor of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK, who was the Principal Investigator of the Phase II clinical trial of ATL1103. Publication of the clinical trial results in a journal having one of the highest impact factors in the field would provide additional verification of the quality of the trial and aid the Company’s future development and partnering plans for ATL1103 in acromegaly."
I'm excited$$$
"
Ann: ATL1103 Update, page-16
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $79.83M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.7¢ | $173.1K | 2.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 477180 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 1063766 | 4 |
View Market Depth
| Last trade - 13.01pm 05/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |